A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis
Diseases of the Nervous System
What is the purpose of this trial?
The purpose of this study is to evaluate the safety, tolerability, and efficacy of M281 administered to participants with generalized myasthenia gravis (gMG) who have an insufficient clinical response to ongoing standard of care therapy.
- Ages18 years and older
- Trial withMomenta Pharmaceuticals, Inc.
- Start Date04/23/2019
- End Date01/30/2020
- Last Updated07/03/2019
- Study HIC#2000024853